LRRC38 Inhibitors
LRRC38 inhibitors are a collection of chemical compounds that suppress the functional activity of LRRC38 by targeting various signaling pathways integral to its activity. Wortmannin and LY 294002, both PI3K inhibitors, disrupt the PI3K/AKT signaling cascade, potentially diminishing LRRC38's role in this pathway. Rapamycin serves as an mTOR inhibitor, impeding the mTORC1 pathway, which could decrease LRRC38 function in mTORC1-linked cellular processes. Similarly, PD 98059 and U0126, which inhibit the MEK enzymes of the MAPK pathway, along with SB 203580, a p38 MAPK inhibitor, and SP600125, a JNK inhibitor, can reduce LRRC38 activity if it is involved in the MAPK-regulated signaling events. PP 2 and Dasatinib, both targeting Src family tyrosine kinases, and Imatinib, known to inhibit BCR-ABL and other tyrosine kinases, could also lead to a decrease in LRRC38 activity if it is functionally active downstream of these kinases.
Additionally, Triciribine, an AKT inhibitor, may lead to a reduction in LRRC38 activity by preventing AKT activation, which is pivotal for many cellular functions. BIX 02189, which selectively inhibits MEK5, a component of the MAPK/ERK5 pathway, could further contribute to the inhibition of LRRC38 if it is implicated in ERK5-mediated signaling. The actions of these inhibitors converge to attenuate the biological processes that are crucial for LRRC38's functional activity, thereby effectively decreasing its influence in cellular signaling without affecting its expression levels. Through the specific inhibition of these pathways, the compounds collectively serve to diminish the activity of LRRC38, impacting its role in cell signaling and regulatory mechanisms.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of phosphoinositide 3-kinases (PI3K), which leads to the inhibition of the AKT signaling pathway. Since LRRC38 is involved in pathways related to cell proliferation and survival that are regulated by AKT, inhibition of PI3K by Wortmannin would lead to decreased activity of LRRC38. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a selective inhibitor of PI3K. It blocks the PI3K/AKT pathway, thus diminishing the downstream signaling that may involve LRRC38, subsequently leading to the inhibition of LRRC38 functional activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that impedes the mTORC1 pathway, which is connected to cell growth and proliferation. By inhibiting mTORC1, Rapamycin could decrease the functional activity of LRRC38 if LRRC38 is involved in these mTORC1-regulated processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a selective inhibitor of MEK, which works upstream of the ERK pathway, part of the MAPK signaling cascade. Inhibition of this pathway can lead to reduced activity of proteins such as LRRC38 if they are implicated in cell signaling events mediated by ERK. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 specifically inhibits p38 MAPK, another branch of the MAPK signaling pathway. If LRRC38 is part of processes influenced by p38 MAPK, its activity would be diminished by the action of SB 203580. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of JNK, which is also part of the MAPK family involved in stress and inflammatory responses. By inhibiting JNK, SP600125 could indirectly lead to decreased functional activity of LRRC38 if it is implicated in JNK-related signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP 2 is a selective inhibitor of Src family tyrosine kinases. If LRRC38 is functionally active downstream of Src kinase signaling, PP 2 would lead to a decrease in LRRC38 activity by inhibiting its upstream kinases. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway. By blocking MEK1/2, U0126 would indirectly decrease the functional activity of LRRC38 if LRRC38 operates within this signaling pathway. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that primarily targets BCR-ABL, c-KIT, and PDGFR. If LRRC38 is functionally activated by these kinases, its activity would be diminished by Imatinib. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine is an AKT inhibitor that prevents the phosphorylation and activation of AKT. By inhibiting AKT, Triciribine could lead to reduced activity of LRRC38 if LRRC38 is involved in AKT-regulated processes. | ||||||